Triple GIP, GLP-1, and glucagon receptor agonist. Once weekly.
Catalog reviewed Sep 30, 2026. Feed checks and price reviews are dated separately below. How we verify. Not medical advice.
An ingredient can have several brands, formulations, and approved uses. Prices and trial findings belong to the specific product and dose shown.
TRIUMPH-1 (Phase 3) · 12 mg weekly (TRIUMPH-1)
TRIUMPH-2 (Phase 3 T2D)
TRIUMPH-1 (12 mg, 80 wks, obesity)
Investigational. Not FDA-approved.
Trial averages are not personal predictions. Weight-loss, A1c, and side-effect figures may come from different trials, doses, or populations; follow each source for its context.
Obesity; type 2 diabetes (investigational)
An investigational triple agonist targeting the GIP, GLP-1, and glucagon receptors; the glucagon arm is intended to increase energy expenditure.
Choose the named product and route. These are submitted label records, which may differ from current approved prescribing information. The product links above lead to current prescribing information. Indexed text omits tables and images; always read the full source label.
No approved label (investigational)
Retatrutide is investigational. See its registered studies below. Search DailyMed.
Reported adverse events and treatment discontinuation from the cited trial. These figures do not predict an individual response.
Discontinued for side effects
11.3% (11.3% vs 4.9% placebo (12 mg) · TRIUMPH-1 (12 mg, 80 wks, obesity))
Reported as 11.3% vs 4.9% placebo (12 mg). The share of trial participants who stopped treatment because of adverse events. This does not measure all side effects or all reasons for stopping.
Had nausea
42.4% (Nausea in the drug arm · TRIUMPH-1 (12 mg, 80 wks, obesity))
The share of participants who reported nausea in this trial. Severity and duration are not captured by this percentage.
Nausea, diarrhea, constipation, and vomiting were the most common events, more frequent than placebo and generally mild-to-moderate, mainly during dose escalation.
From TRIUMPH-1 (12 mg, 80 wks, obesity) (Phase 3 sponsor topline (not yet peer-reviewed)). Tolerability figures come from each drug's own trial (different doses, durations, and populations), so compare them as a guide, not a head-to-head. Source.
30 of 33 registered studies indexed. Showing up to 12 records: posted results first, then late-phase trials. Registry counts are not a measure of evidence quality.
Selected primary outcome
Results · Sep 25, 2026 UTCMean Percent Change From Baseline in Body Weight
Least-squares mean · percent change · Baseline, Week 24
Analysis population: All randomized participants who had baseline and at least one post-baseline body weight value, excluding participants discontinuing study drug due to inadvertent enrollment and data after discontinuation of study drug.
Enforcement records describe specific recalled products and lots. They do not establish the recall status of every product containing the ingredient. openFDA does not maintain current recall status after classification; read the FDA record and any manufacturer notice for details.
1 indexed product record, ordered by FDA report date. One recall event may include several products.
Recalling firm: GenoGenix LLC
Retatrutide for Injection, 60mg / 10mL vial, all presentations, GenoGenix, LLC, 2840 NW 2nd Ave Ste 204 Boca Raton, FL 33431-6692
Reason for recall
Lack of Assurance of Sterility
Browse the FDA enforcement archive · Source coverage & limitations
Overall outcome: 68 Participants analyzed
Overall outcome: 69 Participants analyzed
Overall outcome: 33 Participants analyzed
Overall outcome: 33 Participants analyzed
Overall outcome: 35 Participants analyzed
Overall outcome: 35 Participants analyzed
Overall outcome: 62 Participants analyzed
Least squares (LS) means were calculated using a mixed-effects model for repeated measures (MMRM) for post-baseline measures: Variable = Treatment\*Time + Baseline BMI (\< 36kg/m2 vs. \>=36 kg/m2)\*Time + Sex (Female vs. Male)\*Time + Baseline\*Time.
Placebo: Participants received placebo matched to LY3437943 administered as SC injection QW.
1 mg LY3437943: Participants received 1 mg LY3437943 administered as SC injection QW.
4 mg LY3437943 (2 mg): Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 administered as SC injection QW.
4 mg LY3437943: Participants received 4 mg LY3437943 administered as SC injection QW.
8 mg LY3437943 (2 mg): Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 and then 8 mg LY3437943 administered as SC injection QW.
8 mg LY3437943 (4 mg): Participants received 4 mg LY3437943 starting dose followed by 8 mg LY3437943 administered as SC injection QW.
12 mg LY3437943 (2 mg): Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943, 8 mg LY3437943 and then 12 mg LY3437943 administered as SC injection QW.
One of 1 registered primary outcome, selected for its reported data and weight or blood-sugar endpoint where available. These are registry values; published analyses may differ. Full results on ClinicalTrials.gov.
Source: ClinicalTrials.gov API v2 · as of Oct 3, 2026
All trials on ClinicalTrials.gov